Pharmacokinetic considerations in the repositioning of mefloquine for treatment of progressive multifocal leukoencephalopathy

Clinical Neurology and Neurosurgery

Volumn 114, Issue 8, 2012, Pages 1204-1205

  Nevin, Remington Lee ^a  

^a Bayne Jones Army Community Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; HEMOGLOBIN; LOPERAMIDE; MEFLOQUINE; MEMBRANE PHOSPHOLIPID; MULTIDRUG RESISTANCE PROTEIN 1; ONDANSETRON; PLASMA PROTEIN; QUINIDINE;

BINDING AFFINITY; BLOOD BRAIN BARRIER; DISTRIBUTION VOLUME; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG REPOSITIONING; GENETIC POLYMORPHISM; HUMAN; JC VIRUS; LETTER; NONHUMAN; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;

EID: 84865498196     PISSN: 03038467     EISSN: 18726968     Source Type: Journal    
DOI: 10.1016/j.clineuro.2012.02.046     Document Type: Letter

References (29)

1. Hirayama M, Nosaki Y, Matsui K, Terao S, Kuwayama M, Tateyama H, et al. Efficacy of mefloquine to progressive multifocal leukoencephalopathy initially presented with parkinsonism. Clin Neurol Neurosurg, doi:org/10.1016/j.clineuro. 2011.12.010, in press.
2. T.E. Gofton, A. Al-Khotani, B. O'Farrell, L.C. Ang, and R.S. McLachlan Mefloquine in the treatment of progressive multifocal leukoencephalopathy J Neurol Neurosurg Psychiatry 82 2011 452 455
3. S. Kishida, and K. Tanaka Mefloquine treatment in a patient suffering from progressive multifocal leukoencephalopathy after umbilical cord blood transplant Intern Med 49 2010 2509 2513
4. A. Schröder, D.H. Lee, K. Hellwig, C. Lukas, R.A. Linker, and R. Gold Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis Arch Neurol 67 2010 1391 1394
5. D. Focosi, T. Marco, R.E. Kast, F. Maggi, L. Ceccherini-Nelli, and M. Petrini Progressive multifocal leukoencephalopathy: what's new? Neuroscientist 16 2010 308 323
6. R. Friedman News from the AAN Annual Meeting: Malaria Drug Fails to Fulfill Promise in PML Neurol Today 11 2011 8
7. M. Brickelmaier, A. Lugovskoy, R. Kartikeyan, M.M. Reviriego-Mendoza, N. Allaire, and K. Simon Identification and characterization of mefloquine efficacy against JC virus in vitro Antimicrob Agents Chemother 53 2009 1840 1849
8. J.M. de Souza, P. Heizmann, and D.E. Schwartz Single-dose kinetics of mefloquine in Brazilian male subjects Bull World Health Organ 65 1987 353 356
9. D.E. Schwartz, W. Weber, D. Richard-Lenoble, and M. Gentilini Kinetic studies of mefloquine and of one of its metabolites, Ro 21-5104, in the dog and in man Acta Trop 37 1980 238 242
10. R.A. Pennie, G. Koren, and C. Crevoisier Steady state pharmacokinetics of mefloquine in long-term travellers Trans R Soc Trop Med Hyg 87 1993 459 462
11. B.G. Charles, A. Blomgren, P.E. Nasveld, S.J. Kitchener, A. Jensen, and R.M. Gregory Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment Eur J Clin Pharmacol 63 2007 271 278
12. J.Y. Mu, Z.H. Israili, and P.G. Dayton Studies of the disposition and metabolism of mefloquine HCl (WR 142,490), a quinolinemethanol antimalarial, in the rat. Limited studies with an analog, WR 30,090 Drug Metab Dispos 3 1975 198 210
13. R.S. Rozman, N.A. Molek, and R. Koby The absorption, distribution, and excretion in mice of the antimalarial mefloquine, erythro-2,8- bis(trifluoromethyl)-alpha-(2-piperidyl)-4-quinolinemethanol hydrochloride Drug Metab Dispos 6 1978 654 658
14. R. Jones, G. Kunsman, B. Levine, M. Smith, and C. Stahl Mefloquine distribution in postmortem cases Forensic Sci Int 68 1994 29 32
15. R. Chevli, and C.D. Fitch The antimalarial drug mefloquine binds to membrane phospholipids Antimicrob Agents Chemother 21 1982 581 586
16. R.C. San George, R.L. Nagel, and M.E. Fabry On the mechanism for the red-cell accumulation of mefloquine, an antimalarial drug Biochim Biophys Acta 803 1984 174 181
17. R. Kerb, R. Fux, K. Mörike, P.G. Kremsner, J.P. Gil, and C.H. Gleiter Pharmacogenetics of antimalarial drugs: effect on metabolism and transport Lancet Infect Dis 9 2009 760 774
18. E. Milner, J. Sousa, B. Pybus, V. Melendez, S. Gardner, and K. Grauer Characterization of in vivo metabolites of WR319691, a novel compound with activity against Plasmodium falciparum Eur J Drug Metab Pharmacokinet 3 2011 151 158
19. G.S. Dow, E. Milner, I. Bathurst, J. Bhonsle, D. Caridha, and S. Gardner Central nervous system exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous dosing in mice Malar J 10 2011 150
20. S. Barraud de Lagerie, E. Comets, C. Gautrand, C. Fernandez, D. Auchere, and E. Singlas Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice Br J Pharmacol 141 2004 1214 1222
21. Y.T. Pham, F. Nosten, R. Farinotti, N.J. White, and F. Gimenez Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria Int J Clin Pharmacol Ther 37 1999 58 61
22. I. Cascorbi P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations Handb Exp Pharmacol 201 2011 261 283
23. Y.T. Pham, A. Régina, R. Farinotti, P. Couraud, I.W. Wainer, and F. Roux Interactions of racemic mefloquine and its enantiomers with P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT Biochim Biophys Acta 1524 2000 212 219
24. C. Skarke, M. Jarrar, H. Schmidt, G. Kauert, M. Langer, and G. Geisslinger Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers Pharmacogenetics 13 2003 651 660
25. J.A. Scott, M. Wood, and P. Flood The pronociceptive effect of ondansetron in the setting of Pglycoprotein inhibition Anesth Analg 103 2006 742 746
26. J. Karbwang, K.N. Bangchang, A. Thanavibul, Y. Wattanakoon, and T. Harinasuta Quinine toxicity when given with doxycycline and mefloquine Southeast Asian J Trop Med Public Health 25 1994 397 400
27. R.L. Nevin Mefloquine Blockade of Connexin 36 and Connexin 43 Gap junctions and risk of suicide Biol Psychiatry 71 2012 e1 e2
28. A.L. Aarnoudse, R.H. van Schaik, J. Dieleman, M. Molokhia, M.M. van Riemsdijk, and R.J. Ligthelm MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine Clin Pharmacol Ther 80 2006 367 374
29. N. Zaigraykina, and I. Potasman Polymorphism at the MDR1 locus as a cause of mefloquine-induced psychosis Harefuah 149 2010 583 584 (article in Hebrew)